ISSN: 1618-7598

Journal Home

Journal Guideline

European Journal of Health Economics Q1 Unclaimed

Springer Verlag Germany

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

European Journal of Health Economics is a journal indexed in SJR in Economics, Econometrics and Finance (miscellaneous) and Health Policy with an H index of 67. It has a price of 2990 €. It has an SJR impact factor of 1,08 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,08.

European Journal of Health Economics focuses its scope in these topics and keywords: treatment, health, cancer, model, state, strategies, effects, colorectal, costs, changing, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Economics, Econometrics and Finance (miscellaneous) (Q1) Health Policy (Q1)

Price

2990 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

1,08

SJR Impact factor

67

H Index

162

Total Docs (Last Year)

337

Total Docs (3 years)

7361

Total Refs

1355

Total Cites (3 years)

307

Citable Docs (3 years)

3.32

Cites/Doc (2 years)

45.44

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

American Economic Journal: Applied Economics Q1
Journal of the European Economic Association Q1
American Economic Journal: Economic Policy Q1
American Economic Journal: Microeconomics Q1
Structural Equation Modeling Q1

Compare this journals

Aims and Scope

Best articles by citations

The assessment of the economic return from controlled clinical trials

Comparison of general practitioner records and patient self-report questionnaires for estimation of costs

Impact of unemployment on self-perceived health

Do physicians accept quality of life and utility measurement?

Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy

A comparison of the EuroQol and the Health Utilities Index in patients treated for congenital anomalies

Metal on metal hip resurfacing arthroplasty

Exponential health utility

A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK

Cost-utility of interferon beta 1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis

Economic evaluation of human papillomavirus screening in Germany

SHOW MORE ARTICLES

Is therapeutic innovation responsible for the increase in drug expenditure?

Influence of surgical and treatment choices on the cost of breast cancer care

Gemeindenahe stationäre Versorgung fur Schizophreniepatienten

The reimbursable incontinence pads market for outpatients in five European countries

The role of prices in drug expenditure analysis

Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine

Prevalence and treatment costs of type 2 diabetes in Germany and the effects of social and demographical differences

Financial incentives and the supply of laboratory tests

Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines

Examining the determinants of drug launch delay in pre-TRIPS India

The heterogeneity of markets for drugs in Europe

Medical and economic evaluation of an integrated system of automated analysis in cellular hematology (Sysmex HST-330)